Key Highlights
- Precigen shares are trading up 10.18% today to $7.20, extending gains after the market opened this morning.
- Second-quarter revenue reached $55.0 million, nearly double the $28.4 million analyst estimate.
- PAPZIMEOS net revenue surged to $53.1 million, up more than 145% from $21.6 million in the first quarter.
- The company swung to a diluted EPS of $0.05 versus an expected loss, with net income of $20.1 million for the quarter.
- PAPZIMEOS has now received FDA seven-year market exclusivity through August 2032, alongside expanding payer coverage to approximately 315 million covered lives.
What's Driving Shares Today
Precigen (NASDAQ:PGEN) is a Germantown, Maryland-based biopharmaceutical company advancing next-generation gene and cell therapies to address serious diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company leverages proprietary precision technology platforms, including UltraCAR-T, AdenoVerse, ActoBiotics, and UltraVector, to design, engineer, and manufacture differentiated therapeutic candidates.
Shares are extending gains today after the company delivered a blowout second-quarter earnings report post-close on August 4. Revenue surged to $55.0 million, nearly double the $28.4 million analyst estimate, driven by strong commercial uptake of PAPZIMEOS, its gene therapy for recurrent respiratory papillomatosis approved in August 2025.
PAPZIMEOS Adoption Accelerating
President and CEO Helen Sabzevari said the company delivered a historic second quarter, with rapid PAPZIMEOS adoption demonstrating the strength of its commercial strategy. PAPZIMEOS net revenue reached $53.1 million in the quarter, more than double the $21.6 million generated in the first quarter, a sequential increase of more than 145% that drove Precigen to its first quarter of net profitability. Total launch-to-date revenue for the product now exceeds $78 million, with payer coverage expanding to approximately 315 million covered lives, adding roughly 18 million in the second quarter alone.
The permanent J code implementation is helping drive account activation across both major medical centers and community practices, with clinical durability data presented at ASCO showing 83% of patients remain in ongoing complete response beyond three years. The FDA also granted PAPZIMEOS seven-year market exclusivity for adult patients through August 2032.
Pipeline and Cash Position
Precigen expects PAPZIMEOS gross margin to stabilize in the high-80% to low-90% range once remaining prelaunch inventory is depleted, likely in the third quarter. The company reiterated that current cash, cash equivalents, and investments of $38.7 million, together with proceeds from PAPZIMEOS revenue and collection of accounts receivable, are expected to fund operations through cash flow break-even by the end of 2026. On the pipeline side, a pediatric PAPZIMEOS trial is expected to initiate this year, an EMA marketing authorization application is under review, and PRGN-2009 targeting HPV 16/18 cancers continues advancing in Phase 2 trials combined with pembrolizumab.
Conclusion
Precigen's more than doubling of PAPZIMEOS revenue and swing to profitability mark a pivotal transition from clinical-stage to commercial-stage biopharmaceutical company, with broadening payer coverage and physician adoption suggesting the growth trajectory has room to continue. Today's gains reflect growing investor confidence that this commercial momentum can be sustained as the company approaches the one-year anniversary of PAPZIMEOS's approval.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...